Ranked #8,233 of 8,699 institutional investors
Velan Capital Investment Management LP
Alpharetta, GA
$81.5M
US stock portfolio at live prices · today −$2.1M (−2.55%)
Live prices, last trade 12:54 PM ET
- Value at quarter end (Q3 2026)
- $105M
- Change from Q2 2026
- −$58.6M (−35.90%)
- Positions
- 41 · 6 new, 12 sold out
- Filed
- Nov 16, 2026
Not counted in the ranking: call options on $130K of stock. $1.3M of holdings we could not match to a US listing are included at their reported quarter-end value.
Holdings
Q3 2026 13F, live pricesPRAX 28.8%IMMX 9.41%TARA 7.92%XNCR 7.17%ABVX 5.97%
| Stock | Shares | Value, live | % of portfolio | vs Q2 2026 |
|---|---|---|---|---|
| PRAX Praxis Precision Medicines, Inc. | 76,600 | $23.5M | 28.8% | Reduced −14% |
| IMMX Immix Biopharma, Inc. | 1,085,000 | $7.7M | 9.41% | Unchanged |
| TARA Protara Therapeutics, Inc. | 2,844,652 | $6.5M | 7.92% | Unchanged |
| XNCR Xencor, Inc. | 175,000 | $5.8M | 7.17% | Reduced −31% |
| ABVX ABIVAX Société Anonyme | 65,630 | $4.9M | 5.97% | Unchanged |
| STRO Sutro Biopharma, Inc. | 510,038 | $4.4M | 5.39% | Reduced −0% |
| MPLT MapLight Therapeutics, Inc. | 624,703 | $3.8M | 4.72% | Added +27% |
| AVR Anteris Technologies Global Corp. | 700,000 | $3.5M | 4.24% | Unchanged |
| EVMN Evommune Inc | 456,255 | $3.2M | 3.95% | Added +1% |
| EDSA Edesa Biotech, Inc. | 1,282,045 | $2.7M | 3.27% | Added +55% |
| HRTX Heron Therapeutics, Inc. | 8,753,290 | $2.2M | 2.75% | Unchanged |
| AVTX Avalo Therapeutics, Inc. | 324,452 | $2.2M | 2.68% | Unchanged |
| EPRX Eupraxia Pharmaceuticals Inc. | 352,000 | $2.1M | 2.54% | Unchanged |
| EWTX Edgewise Therapeutics, Inc. | 34,250 | $1.4M | 1.69% | New |
| QTTB Q32 Bio Inc. | 120,000 | $1.0M | 1.24% | New |
| RNTX Rein Therapeutics Inc. | 1,700,000 | $610K | 0.75% | Unchanged |
| NSPR InspireMD, Inc. | 924,680 | $514K | 0.63% | Added +524% |
| PTGX Protagonist Therapeutics, Inc. | 3,700 | $452K | 0.55% | Unchanged |
| REPL Replimune Group, Inc. | 20,000 | $379K | 0.46% | Unchanged |
| VRDN Viridian Therapeutics, Inc. | 10,000 | $305K | 0.37% | Unchanged |
| DTIL Precision BioSciences, Inc. | 40,000 | $290K | 0.36% | Unchanged |
| OVID Ovid Therapeutics Inc. | 130,000 | $285K | 0.35% | Unchanged |
| CTMX CytomX Therapeutics, Inc. | 120,000 | $248K | 0.30% | Unchanged |
| NRIX Nurix Therapeutics, Inc. | 16,000 | $208K | 0.26% | Unchanged |
| LYEL Lyell Immunopharma, Inc. | 15,000 | $203K | 0.25% | Reduced −86% |
| ANTX AN2 Therapeutics, Inc. | 40,000 | $202K | 0.25% | Unchanged |
| ZLAB Zai Lab Limited | 9,000 | $188K | 0.23% | New |
| CCCC C4 Therapeutics, Inc. | 70,000 | $175K | 0.21% | Reduced −88% |
| IMNM Immunome, Inc. | 10,000 | $160K | 0.20% | Unchanged |
| MLYS Mineralys Therapeutics, Inc. | 11,000 | $154K | 0.19% | Unchanged |
| JBIO Jade Biosciences, Inc. | 10,000 | $154K | 0.19% | New |
| RCKT Rocket Pharmaceuticals, Inc. | 60,000 | $120K | 0.15% | Unchanged |
| MGNX MacroGenics, Inc. | 60,000 | $120K | 0.15% | Unchanged |
| ENTA Enanta Pharmaceuticals, Inc. | 15,000 | $116K | 0.14% | New |
| SCYX SCYNEXIS, Inc. | 40,000 | $99K | 0.12% | Unchanged |
| LRMR Larimar Therapeutics, Inc. | 33,000 | $99K | 0.12% | Unchanged |
| ARTV Artiva Biotherapeutics, Inc. | 25,000 | $95K | 0.12% | Unchanged |
| AARD Aardvark Therapeutics, Inc. | 85,868 | $78K | <0.1% | New |
| NMRA Neumora Therapeutics, Inc. | 230,000 | $72K | <0.1% | Unchanged |
| CRBP Corbus Pharmaceuticals Holdings, Inc. | 30,000 | $65K | <0.1% | Added +15% |
| KLRS Kalaris Therapeutics, Inc. | 25,000 | $33K | <0.1% | Unchanged |
Sold out in Q3 2026
| Stock | Shares held at Q2 2026 | Worth today |
|---|---|---|
| ADMA ADMA Biologics, Inc. | 250,000 | $3.3M |
| RZLT Rezolute, Inc. | 750,000 | $2.9M |
| VRCA Verrica Pharmaceuticals Inc. | 471,559 | $1.3M |
| PROF Profound Medical Corp. | 170,278 | $1.1M |
| TENX Tenax Therapeutics, Inc. | 549,985 | $696K |
| TECX Tectonic Therapeutic, Inc. | 6,000 | $124K |
| QNRX Quoin Pharmaceuticals, Ltd. | 32,372 | $108K |
| XLO Xilio Therapeutics, Inc. | 14,285 | $105K |
| SNDX Syndax Pharmaceuticals, Inc. | 10,000 | $90K |
| CNTX Context Therapeutics Inc. | 59,700 | $10K |
| GOSS Gossamer Bio, Inc. | 875 | $10K |
| KPTIQ Karyopharm Therapeutics Inc. | 20,000 | $640 |